1-20 of 80
multiple myeloma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

What to do with minimal residual disease testing in myeloma

Elisabet E. Manasanch
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 137–141.
https://doi.org/10.1182/hematology.2019000080
Published: 2019
Journal Articles

Roundtable: How I treat a newly diagnosed patient with high-risk myeloma

Jonathan L. Kaufman
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 120–124.
https://doi.org/10.1182/hematology.2019000015
Published: 2019
Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.
https://doi.org/10.1182/hematology.2019000075
Published: 2019
Journal Articles

How I treat a refractory myeloma patient who is not eligible for a clinical trial

Siyang Leng, Divaya Bhutani, Suzanne Lentzsch
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 125–136.
https://doi.org/10.1182/hematology.2019000016
Published: 2019
Journal Articles

Myeloma: next generation immunotherapy

Adam D. Cohen
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 266–272.
https://doi.org/10.1182/hematology.2019000068
Published: 2019
Journal Articles

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana, Nina Shah
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 260–265.
https://doi.org/10.1182/hematology.2019000370
Published: 2019
Journal Articles

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist

Thierry Facon, Kenneth Anderson
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 83–87.
https://doi.org/10.1182/asheducation-2018.1.83
Published: 2018
Journal Articles

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist

Tanya M. Wildes, Kenneth C. Anderson
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 88–96.
https://doi.org/10.1182/asheducation-2018.1.88
Published: 2018
Journal Articles

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Saad Z. Usmani, Eric Seifter
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 97–102.
https://doi.org/10.1182/asheducation-2018.1.97
Published: 2018
Journal Articles

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Sergio Giralt, Eric Seifter
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 103–109.
https://doi.org/10.1182/asheducation-2018.1.103
Published: 2018
Journal Articles

Is molecular remission the goal of multiple myeloma therapy?

Faith E. Davies
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 205–211.
https://doi.org/10.1182/asheducation-2017.1.205
Published: 2017
Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.
https://doi.org/10.1182/asheducation-2017.1.212
Published: 2017
Journal Articles

Management of multiple myeloma in the newly diagnosed patient

María-Victoria Mateos, Jesús F. San Miguel
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 498–507.
https://doi.org/10.1182/asheducation-2017.1.498
Published: 2017
Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.
https://doi.org/10.1182/asheducation-2017.1.508
Published: 2017
Journal Articles

Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Shaji Kumar
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 518–524.
https://doi.org/10.1182/asheducation-2017.1.518
Published: 2017
Journal Articles

Shall we treat smoldering multiple myeloma in the near future?

Ola Landgren
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 194–204.
https://doi.org/10.1182/asheducation-2017.1.194
Published: 2017
Journal Articles

Myeloma: management of the newly diagnosed high-risk patient

Angela Dispenzieri
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 485–494.
https://doi.org/10.1182/asheducation-2016.1.485
Published: 2016
Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.
https://doi.org/10.1182/asheducation-2016.1.495
Published: 2016
Journal Articles

Advances and practical use of monoclonal antibodies in multiple myeloma therapy

Hans C. Lee, Donna M. Weber
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 512–520.
https://doi.org/10.1182/asheducation-2016.1.512
Published: 2016
Journal Articles

Checkpoint inhibition in myeloma

Don M. Benson, Jr
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 528–533.
https://doi.org/10.1182/asheducation-2016.1.528
Published: 2016